I-Mab is a biopharmaceutical company that is dedicated to discovering and developing innovative biologics to address unmet medical needs. Their corporate philosophy revolves around a patient-centric approach, focusing on improving patients' lives through advanced therapies. I-Mab values integrity, collaboration, and scientific excellence, aiming to provide breakthrough treatments for diseases with high unmet medical needs. With a strong commitment to delivering novel solutions, I-Mab continuously strives to be at the forefront of research and development in the biopharmaceutical industry.

I-Mab is primarily present in China and the United States.

I-Mab, a leading biopharmaceutical company, has achieved significant milestones throughout its journey. The company successfully conducted a Phase 3 clinical trial for its innovative therapy in treating diffuse large B-cell lymphoma, demonstrating its commitment to advancing healthcare solutions. Additionally, I-Mab received the U.S. FDA Fast Track Designation for its potential treatment of multiple myeloma, recognizing the company's dedication to developing breakthrough therapies. Furthermore, I-Mab forged strategic partnerships with renowned global pharmaceutical companies, reinforcing its position in the global market. Overall, I-Mab's achievements highlight its exceptional growth and commitment towards improving patients' lives through groundbreaking treatments.

I-Mab is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2016, I-Mab focuses on the discovery and development of antibody-based drugs by leveraging its proprietary discovery and development platforms. This Chinese company has a strong emphasis on research and development, working on a diverse pipeline of potential drugs targeting various diseases. With a commitment to delivering novel and effective solutions, I-Mab has garnered recognition within the pharmaceutical industry for its innovative approach and dedication to improving patients' lives.

The main competitors of I-Mab in the market include large biopharmaceutical companies such as Junshi Biosciences, Legend Biotech, BeiGene, and Innovent Biologics.

I-Mab is primarily active in the pharmaceutical industry.

I-Mab is a clinical-stage biopharmaceutical company based in China. Its business model revolves around the discovery, development, and commercialization of innovative and differentiated biologics. I-Mab focuses on developing novel antibodies to address unmet medical needs in the fields of oncology, immuno-oncology, and autoimmune diseases. With a strong pipeline of potential therapies, I-Mab aims to bring groundbreaking treatments to patients globally. By advancing its drug candidates through rigorous research and strategic partnerships, I-Mab aims to revolutionize healthcare and improve patient outcomes.

De I-Mab K/W is -4,35.

De I-Mab KUV is 2.605,55.

De AlleAktien Kwaliteitsscore voor I-Mab is 1/10.

De verwachte I-Mab omzet is 765.000,00 CNY.

De verwachte I-Mab winst is -458,28 mln. CNY.

I-Mab is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious diseases like cancer and immune disorders. They have a strong pipeline of products in the fields of oncology, autoimmune diseases, and cardiovascular diseases. They have partnerships with other companies to market their products worldwide. Overall, their business model is centered around developing and marketing effective therapies for challenging diseases and they have a unique partnership strategy.

I-Mab keert een dividend van 0 CNY uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor I-Mab of het bedrijf keert geen dividend uit.

De ISIN van I-Mab is US44975P1030.

Het WKN van I-Mab is A2PVC6.

De ticker van I-Mab is IMAB.

Binnen de laatste 12 maanden betaalde I-Mab een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal I-Mab naar verwachting een dividend van 0 CNY betalen.

De dividendrendement van I-Mab is momenteel .

I-Mab betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

I-Mab betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 CNY verwacht. Dit komt overeen met een dividendrendement van 0 %.

I-Mab wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van I-Mab van 31-7-2024 ter hoogte van 0 CNY te ontvangen, moest je het aandeel voor de ex-datum op 31-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 31-7-2024.

In het jaar 2023 heeft I-Mab 0 CNY aan dividenden uitgekeerd.

De dividenden van I-Mab worden in CNY uitgekeerd.